BioSpace News Archive

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to €40 M. The loan may be used to further support the clinical development of melflufen, and the company’s tran

I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors An u pdate from the melanoma & non-melanoma skin cancer patients enrolled into the Phase 1/2 clinical trial of RP1 in combination with Opdivo® (nivolumab) WOBURN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company deve

Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing.

Nevada’s largest school of medicine equips students with handheld ultrasound technology for enhanced education

Orbis International announced the publication of the Orbis Ophthalmic Nursing Competency Assessment Rubric for scrub nurses and technicians in Insight, the American Society of Ophthalmic Registered Nurses’ peer-reviewed clinical journal.

Safety and Tolerability Established Good and Excellent Functional Outcome Increased YONGIN, South Korea--( BUSINESS WIRE )-- GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and efficacy of nelonemdaz in acute ischemic stroke patients treated with endovascular thrombectomy within 8 hours of symptom onset (SONIC). In this stu

Veracyte, Inc. (Nasdaq: VCYT) announced today that an oral presentation will be given at the CHEST Annual Meeting 2020 reinforcing the foundational technology behind its noninvasive nasal swab test to identify lung cancer risk in patients with lung nodules.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena ® , the only FDA-approved treatment, along with its equivalent generics, to reduce preterm birth. Makena was approved in 2011, based on the landmark NICHD MFMU trial by Meis et al . A second, FDA-required trial ( PROLONG ) predominant

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces enrollment of the 10 th subject in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD). “Patient screening and enroll

The Public Health Agency of Canada is collaborating with provincial and territorial public health and food safety partners to investigate an outbreak of Vibrio parahaemolyticus infections occurring in four provinces.